Inhaled sodium cromoglycate in children with asthma (original) (raw)
Related papers
Iranian Journal of Pharmaceutical Research : IJPR, 2012
Cromolyn sodium, a mast cell stabilizing agent, provides an immediate protective effect against the exercise-induced bronchoconstriction while being used before the exercise. However, cromolyn is ineffective in reversing asthmatic bronchospasm; it is used as a maintenance therapy and has a prophylactic role in chronic asthma. The purpose of this study was to determine the extent of change in baseline lung function tests following a single dose of cromolyn sodium in adult asthmatics. Forty volunteers (33 women and 7 men) with moderate to severe persistent asthma were randomly assigned to receive 20 mg cromolyn, 40 mg cromolyn or cromolyn-placebo. The percent of improvement in lung function parameters was compared among the groups, during 1 h of inhalation. Low dose of cromolyn induced more improvement in most lung function parameters such as forced expiratory flow volume in one second, forced vital capacity and peak expiratory flow compared with other groups. After 15 min, the improv...
Sodium cromoglycate and carbachol-induced bronchoprovocation in asthmatic children
Pediatric Pulmonology, 1987
Ten children with mild bronchial asthma underwent bronchial challenge with carbachol on three consecutive days; using a double-blind technique, they were given inhaled saline placebo on the first day and placebo or sodium cromoglycate (SCG) on the second and third days 15 min prior to the bronchial provocation test with carbachol. We did not find any significant difference between the baseline and placebo values, but we did obtain a statistically significant difference when comparing baseline with post-SCG and placebo with post-SCG values. These results demonstrate a protective effect of SCG on carbachol-induced bronchospasm in asthmatic children. Pediatr Pulmonol 1987;3:161-165.
Evaluation of sodium cromoglycate B.P. (INTAL) in the prophylaxis of bronchial asthma in Asians
Singapore medical journal, 1975
A double-blind cross-over trial was undertaken to determine the prophylactic value of sodium cromoglycate B.P. in patients of Asian stock with bronchial asthma. Statistical analysis of the results showed the drug was superior to placebo in reducing:-(a) the number of acute asthmatic attacks; (b) the bronchodilator requirement The majority of the patients at the end of trial period preferred the drug to the placebo. Slight improvement in the Forced Expiratory Volume ill one second was obtained at the end of the drug period.
Efficacy of cromoglycate in persistently wheezing infants
Archives of Disease in Childhood, 1994
A prospective study was undertaken to evaluate the efficacy of (sodium) cromoglycate in the treatment of persistent wheezing in 31 children between 4 and 12 months of age. The subjects were randomised to receive either 40 mg of cromoglycate (n= 16) or physiological saline as placebo (n= 15) three times a day by wet nebulisation in a double blind fashion for a period of six weeks. The patients were evaluated with daily symptom scores and respiratory function testing measuring maximal expiratory flow at functional residual capacity (V..FRc) before initiating treatment and upon completion. At baseline, mean (SD) symptom scores between the two groups were comparable (cromoglycate 99*5 (29.8), placebo 104-5 (29.7)) as were Vm.FRc expressed as per cent of predicted normals (cromoglycate 48 (28), placebo 46 (20)). Upon completion of the treatment protocol, no significant difference could be found between the two groups for either symptom score (cromoglycate 67-6 (40.2), placebo 58*6 (41-4)), or V,,,FRC (cromoglycate 52 (24), placebo 60 (32)). It is concluded, therefore, that 40 mg of